1800 202 8726
Prostate cancer imaging

PSMA PET vs FDG PET — for Prostate Cancer

The standard PET tracer, FDG, routinely fails to detect prostate cancer. PSMA PET uses an entirely different target and finds disease that FDG cannot see. If your oncologist has recommended PSMA PET, there is a specific reason the standard scan would not answer the clinical question.

Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026

  • FDG and prostate are a poor match — Prostate tumours consume very little glucose, so they produce little to no signal on a standard FDG scan.
  • PSMA tracks a protein, not glucose — PSMA PET attaches to a protein expressed on prostate cancer cells — one that FDG ignores entirely.
  • It detects disease earlier — PSMA PET can find spread at lower PSA levels and smaller tumour volumes than CT or bone scanning alone.
  • Higher cost, targeted use — PSMA PET costs more than FDG PET but is ordered because the clinical question cannot be answered another way.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

FDG PET, the standard scanner used for most cancers, routinely misses prostate cancer because prostate tumours consume very little glucose — the signal FDG depends on. PSMA PET tracks a protein specific to prostate cancer cells and detects disease FDG cannot see. Your oncologist will recommend the right scan based on your PSA and treatment history.

At CION, a whole-body PET-CT starts from Rs 10,499 — among the lowest published prices in Hyderabad. Indicative price, as of September 2026.

Why does a standard PET scan miss prostate cancer?

FDG — fluorodeoxyglucose — is a radioactive sugar that concentrates in tissue with high glucose consumption. Most cancers burn large amounts of glucose, which is what makes them visible on an FDG scan.

Prostate cancer is a biological exception. Most prostate tumours consume very little glucose. They are present but produce almost no FDG signal, so the scan looks normal even when disease is there. This is not a limitation of the machine — it is a mismatch between the tracer and the tumour.

ASCO and ESMO guidance reflects this: FDG PET is generally not recommended for routine prostate cancer staging or recurrence assessment because the biology makes it unreliable for this tumour type.

What can PSMA PET detect that an FDG PET scan cannot?

  • Lymph node spread that is too small to be called suspicious on a CT scan
  • Bone metastases earlier than a standard bone scan typically finds them
  • Biochemical recurrence — rising PSA after treatment — when CT and bone scan are both negative
  • Small-volume disease in the pelvis after surgery or radiotherapy
  • Distant spread that would change whether local salvage treatment is still appropriate

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

PET-CT Partner Centres

PET-CT Scan Centres in Hyderabad

CION offers PET-CT scans through 4 trusted partner PET-CT centres across Hyderabad, so you can choose the one closest to you. Call 18002028726 and we’ll guide you to the earliest available appointment.

These are partner diagnostic centres within the CION network. Toll-free booking: 18002028726.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

When would your oncologist choose PSMA PET instead of FDG PET?

PSMA PET is used most often in three situations: high-risk initial staging where knowing the true extent of disease changes the treatment plan, biochemical recurrence after surgery or radiotherapy where older imaging has found nothing, and assessment before PSMA-targeted therapy where confirming the tumour expresses the protein is required.

FDG PET is rarely used for prostate cancer at all. The exception is very aggressive or treatment-resistant disease that has shifted its metabolic pattern — your oncologist will tell you if that applies. For the vast majority of prostate cancer questions, FDG PET is not the right tool.

The decision about which scan you need is based on your PSA level, your Gleason score, what treatment you have already had, and what your oncologist is trying to find out. A scan is always ordered with a specific clinical question in mind.

What happens at your PSMA PET-CT appointment?

  1. Booking

    PSMA PET-CT is coordinated through partner imaging centres. Availability and tracer supply are confirmed at the time of booking — the radiotracer has a short usable life after production and cannot always be provided on the same day you call.

  2. Preparation

    Unlike FDG PET, PSMA PET does not require you to fast beforehand. Drink water normally and arrive hydrated. Your care team will tell you if any medications need to be paused.

  3. Tracer injection

    The PSMA tracer is given as a small injection into a vein. You will then wait approximately an hour in a quiet area while the tracer circulates and attaches to prostate cancer cells.

  4. The scan

    You lie still on the scanner bed for approximately 20 to 30 minutes. The scan is not painful. You may be asked to empty your bladder beforehand, as the tracer clears partly through the kidneys.

  5. Results

    Images are reported by a nuclear medicine physician. Your oncologist will discuss the findings with you at a follow-up appointment. The scan report describes what was seen — it does not itself determine your treatment.

PET-CT at CION starts from Rs 10,499 — among the lowest published prices in Hyderabad — across 4 partner centres in Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda. Indicative price, as of September 2026.

Explore 72 more Specialised Tracers and How PET-CT Compares topics

All Specialised Tracers and How PET-CT Compares →

Your next step

Talk to an oncologist about your scan

Your PET-CT report read by a senior oncologist, explained in plain language, with a free 45-minute consultation.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Is PSMA PET better than a bone scan for prostate cancer?

For detecting bone metastases, PSMA PET-CT is generally more sensitive than a standard bone scan, and it also assesses lymph nodes and soft tissue in the same examination — something a bone scan does not do. ASCO and ESMO guidance reflects this in high-risk staging and recurrence settings. Your oncologist will tell you which imaging your specific situation calls for, because the right choice depends on your stage, your PSA level, and what decision is being made about your treatment.

Does a negative PSMA PET mean the cancer has not spread?

No, and this is important to understand. A negative PSMA PET means the scan did not detect disease in visible locations at the time it was done. It does not confirm that no cancer cells are present elsewhere. Some spread may be below the resolution the scanner can detect. Your oncologist will interpret the result alongside your PSA trend and your clinical picture. A negative scan is useful information, but it is not a guarantee that the disease is confined.

Why does PSMA PET cost more than a standard FDG PET scan?

PSMA tracers are produced in specialist radiopharmacy facilities and have a short usable life after production, which makes supply and logistics more complex than FDG. The uptake wait time is also longer. At CION partner centres, the indicative cost for PSMA PET-CT is around ₹23,999 — this is a guide, and the confirmed figure should be verified at booking as costs may vary by centre or clinical requirements. Ask your care team for the actual amount before the appointment.

Can I have a PSMA PET if my PSA is very low after surgery?

Yes, and this is one of the situations where PSMA PET has changed clinical practice. It can detect recurrence at PSA levels where older imaging — CT and bone scan — showed nothing at all. Whether it is appropriate for your specific PSA level is a decision your oncologist makes based on your Gleason score, the treatment you received, and how rapidly your PSA is rising. Ask your oncologist what threshold they are using as the trigger for imaging in your case.

Does PSMA PET involve more radiation than a standard PET scan?

The radiation dose from a PSMA PET-CT is broadly comparable to an FDG PET-CT. Both involve a small radiotracer injection and the low-dose CT component. The dose is weighed against the clinical information the scan provides — that balance is part of the reason your oncologist orders it only when it will change what happens next. Your nuclear medicine team can give you the specific dose estimate for the scan you are having.

Will the PSMA PET scan tell my oncologist what treatment I need?

The scan tells your oncologist where disease is visible and how much the imaging can detect. It does not itself decide your treatment. Your oncologist uses the result alongside your PSA, your Gleason score, your general health, and your own priorities to recommend a plan. A scan that finds spread in one lymph node leads to a different conversation than one that finds many distant metastases — but the treatment decision is always made by your team in discussion with you, not by the scan alone.

Call now Book free consultation